References
Drug breakdown: Rivaroxaban
Abstract
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of tweets. This month she is talking about #rivaroxaban
Dr Sharon Rees @reesprescribe
Day 1: As the gateway to the final common clotting pathway, factor Xa (FXa) was defined as a drug target. Mapping of this enzyme's pockets allowed computer aided testing of approximately 200 K small molecules for affinity and selectivity. #rivaroxaban showed high affinity and was licensed in 2008 in UK.
Dr Sharon Rees @reesprescribe
(cont) #rivaroxaban is one of the ‘direct’ oral anti-coagulants, named because it targets a single clotting factor; this reduces pharmacodynamic variability. These drugs (also apixaban and edoxaban) are now known as the ‘new’ oral anticoagulants; referred to as NOACs.
Dr Sharon Rees @reesprescribe
Day 2: VTE prophylaxis post hip/knee surgery 10 mg once daily (od) for 2 weeks (knee replacement) and 5 weeks (total hip repl); Treatment for DVT/PE 15 mg twice daily 21days then 20mg od. Prophylaxis of stroke/syst embolism 20 mg od; Prophylaxis thrombotic events in acute coronary syndrome and coronary/peripheral artery disease 2.5 mg twice daily (usually for 12 months ACS) (not exhaustive).
Register now to continue reading
Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to our clinical or professional articles
-
New content and clinical newsletter updates each month